Many women experienced lingering depression throughout pregnancy and postpartum, despite using SSRI antidepressants, a new study reports.
People with untreated depression have lower levels of mitochondrial proteins. For those who responded to the SSRI antidepressants, the proteins returned to a normal level, but showed no increase in those who did not respond to medication.
A comparison of medical records reveals people who took SSRI antidepressants, specifically fluoxetine (Prozac), were less likely to die of COVID-19 than a matched control group. The findings add to a growing body of evidence that SSRIs may have beneficial effects against the worst symptoms of coronavirus.
The placebo effect combined with dopamine levels can determine whether symptoms of depression and social anxiety will improve in patients prescribed SSRI antidepressants. Researchers found the positive effect of the medications was four times higher in patients with high expectations the treatment would work compared to those with lower expectations.
Prozac reduced polyunsaturated fatty acid lipid concentrations in the brains of juvenile macaque monkeys.
A new study adds to the growing body of research linking inflammation to depression. Researchers found the molecule histamine directly inhibits the release of serotonin in the brain by attaching to inhibitory receptors on serotonin neurons in mice.
Taking SSRI antidepressants does not increase the risk of developmental delays or autism in children, a new study reports. However, there is an increased risk for ASD and developmental delays in children whose mothers suffer from maternal psychiatric disorders.
Prescribing SSRIs during late childhood to those with genetic risk factors for psychosis can reduce the deterioration of intellectual abilities, a new study reveals. SSRIs appear to have a neuroprotective effect for certain brain areas associated with the onset of psychosis if provided early.
SSRI's, ketamine, and tricyclic antidepressants all bind with TrkB. The findings challenge the roles serotonin and glutamate receptors play in the effects of antidepressant medications.
With the risk of potential for abuse, some new fast-acting antidepressants, like Ketamine, may not be a magic "cure-all" for depression.
Activity of the c-Fos gene begins the increase on the ninth day of exposure to antidepressants. By day 14, mice showed behavioral changes associated with SSRI use. This may explain why suicide rates drop after nine days of treatment, and symptoms of depression improve after three weeks.
The antipsychotic medication clozapine can trigger severe obsessive-compulsive symptoms (OCS) in patients. Adding aripiprazole can help manage clozapine-associated OCS.
